Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, and repair. Key product lines include orthopedic/joint health (ORTHOVISC, MONOVISC), ophthalmic viscoelastics (AMVISC), aesthetic dermatology (HYDRELLE/ELEVESS), and veterinary products (HYVISC).
Material Event: On December 30, 2009, Anika acquired 100% of Fidia Advanced Biopolymers S.r.l. ("FAB"), an Italian company with over 20 commercialized HA products, for a total consideration of approximately $33.9 million ($17.1 million cash and $16.8 million in stock). This acquisition expanded Anika's portfolio into advanced wound care, surgical/anti-adhesion, and ENT markets.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Revenue | $40.1 million | $35.8 million |
| Product Revenue | $37.3 million | $33.1 million |
| Net Income | $3.7 million | $3.6 million |
| Diluted EPS | $0.32 | $0.32 |
| Product Gross Margin | 63% | 60% |
| Operating Cash Flow | $3.1 million | $3.4 million |
| Cash & Equivalents (Year End) | $24.4 million | $43.2 million |
| Long-Term Debt | $14.4 million | $16.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 12% to $40.1 million, driven primarily by a 22% increase in Joint Health product revenue ($22.9 million) and a 191% surge in Aesthetic Dermatology revenue ($1.5 million) following the appointment of a new U.S. distributor (Coapt Systems).
- Product Mix Shift: Joint Health products now represent 61% of product revenue (up from 57% in 2008). Conversely, Veterinary revenue declined 25% to $2.3 million due to inventory management by the distributor.
- Acquisition Impact: The acquisition of FAB resulted in $2.2 million of non-recurring acquisition-related expenses in 2009. While FAB's operating results were immaterial for the single day of ownership in 2009, the transaction significantly increased intangible assets and goodwill on the balance sheet.
- Liquidity: Cash and cash equivalents decreased by approximately $18.8 million, primarily due to the $17.1 million cash payment for the FAB acquisition and capital expenditures for the new Bedford facility.
- Interest Income: Net interest income turned to a net expense of $74,480 in 2009 (compared to $498,512 income in 2008) due to lower interest rates and reduced cash balances.
Guidance, Outlook, and Risks
- Outlook: Management expects Joint Health revenue to increase in 2010. Aesthetic revenue growth is expected to be modest due to market competition. The company anticipates a small decline in gross margin in 2010 due to the transition of manufacturing operations to the new Bedford facility.
- Regulatory Milestones: Anika filed a Premarket Approval (PMA) application for MONOVISC in the U.S. in December 2009, expecting FDA approval in the second half of 2010. The company is also pursuing U.S. approval for several FAB orthopedic products.
- Manufacturing Transition: Validation of the new Bedford manufacturing facility is expected to be completed in 2010. The transition may cause temporary manufacturing inefficiencies.
- Key Risks:
- FDA Warning Letter: The company received an FDA Warning Letter in 2008 regarding its Woburn facility. While corrective actions have been accepted, follow-up inspections in 2009 noted deficiencies. Clearance of the Warning Letter is critical for operations.
- Customer Concentration: Four customers accounted for 83% of product revenue in 2009, including Bausch & Lomb (27% of product revenue) and DePuy Mitek (45% of product revenue).
- Integration Risk: Successfully integrating FAB's operations and turning the subsidiary from a loss-making entity into a profitable one is a stated goal but carries execution risk.
- Debt Covenants: The company must maintain specific financial ratios under its Credit Agreement with Bank of America.
Investor Verification Checklist
- FDA Status: Verify the current status of the FDA Warning Letter clearance and the timeline for the MONOVISC PMA approval.
- Customer Concentration: Monitor the renewal status of the supply agreement with Bausch & Lomb (expires Dec 31, 2010) and sales performance with DePuy Mitek.
- Acquisition Integration: Assess the progress of integrating FAB's products into the U.S. market and the realization of synergies.
- Manufacturing Transition: Track the completion of the Bedford facility validation and any impact on production capacity or gross margins.
- Liquidity: Confirm that operating cash flows remain sufficient to fund the transition costs and R&D without requiring immediate additional financing.